AI English summary of an SEC filing — figures as filed
Johnson & Johnson JNJJohnson & Johnson said worldwide sales for the fiscal first quarter of 2024 rose 2.3% to $21.4 billion. The increase included operational growth of 3.9% and a negative currency impact of 1.6%. Sales for Q1 2023 were $20.9 billion.
Key points
AI summaryJohnson & Johnson said worldwide sales for the fiscal first quarter of 2024 rose 2.3% to $21.4 billion. The increase included operational growth of 3.9% and a negative currency impact of 1.6%. Sales for Q1 2023 were $20.9 billion.
The company said Innovative Medicine segment sales for Q1 rose 1.1% to $13.6 billion, and MedTech segment sales rose 4.5% to $7.8 billion. It said the decline in Covid-19 Vaccine sales had a negative impact of 5.8% on Innovative Medicine operational sales.
Johnson & Johnson said pre-tax earnings were $3.7 billion, or 17.4% of sales, for Q1 2024, compared with a loss of $1.3 billion, or (6.2)% of sales, for Q1 2023. The company also disclosed that talc-related charges were included in 2024 and Q1 2023 of $2.7 billion and $6.9 billion, respectively.
The company said cash, cash equivalents and marketable securities were approximately $26.2 billion as of March 31, 2024, while notes payable and long-term debt were approximately $33.6 billion, for a net debt position of $7.4 billion. It said operating cash flow for Q1 was $3.7 billion.
Key figures
Quarter ended March 31, 2024
- Revenue
- $21.4B
- Net income
- $3.3B
- EPS
- $1.34
- Gross profit
- $14.9B
- Operating cash flow
- $3.7B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Johnson & Johnson Q1 2024 worldwide sales $21.4 billion
Johnson & Johnson said worldwide sales for the fiscal first quarter of 2024 rose 2.3% to $21.4 billion. The increase included operational growth of 3.9% and a negative currency impact of 1.6%. Sales for Q1 2023 were $20.9 billion.
Source · Based on the MD&A text of the filing
Innovative Medicine and MedTech segment sales
The company said Innovative Medicine segment sales for Q1 rose 1.1% to $13.6 billion, and MedTech segment sales rose 4.5% to $7.8 billion. It said the decline in Covid-19 Vaccine sales had a negative impact of 5.8% on Innovative Medicine operational sales.
Source · Based on the MD&A text of the filing
Pre-tax earnings $3.7 billion and talc-related charges
Johnson & Johnson said pre-tax earnings were $3.7 billion, or 17.4% of sales, for Q1 2024, compared with a loss of $1.3 billion, or (6.2)% of sales, for Q1 2023. The company also disclosed that talc-related charges were included in 2024 and Q1 2023 of $2.7 billion and $6.9 billion, respectively.
Source · Based on the MD&A text of the filing
Cash and debt position
The company said cash, cash equivalents and marketable securities were approximately $26.2 billion as of March 31, 2024, while notes payable and long-term debt were approximately $33.6 billion, for a net debt position of $7.4 billion. It said operating cash flow for Q1 was $3.7 billion.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…